AQST Investors Encouraged to Seek Lead Plaintiff Role in Aquestive Therapeutics Securities Class Action Case with Johnson Fistel

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. for allegedly providing misleading information regarding its New Drug Application for Anaphylm, leading to investor losses during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Aquestive Therapeutics securities between June 16, 2025, and January 8, 2026 [1]. - Investors have until May 4, 2026, to seek appointment as lead plaintiff if they suffered losses during the Class Period [2]. - The complaint alleges that the defendants made positive statements while concealing material adverse facts about the NDA for Anaphylm [3]. Group 2: Regulatory Issues - On January 9, 2026, Aquestive announced it received a letter from the FDA identifying deficiencies that hindered labeling discussions for Anaphylm [3]. - The FDA's letter confirmed that the review of Anaphylm's NDA was ongoing, delaying approval beyond the January 31, 2026, Prescription Drug User Fee Act date [3]. Group 3: Company Background - Johnson Fistel, PLLP is a law firm specializing in shareholder rights and has recovered approximately $90.7 million for investors in previous cases [4].